Tyrogenex is studying X-82, a VEGFR/PGDFR/CSF-1R dual kinase inhibitor, in different types of solid tumors as part of a combination therapy regimen.
Combination Trial with Docetaxel in Solid Tumors
With the University of Wisconsin as the sponsor, Tyrogenex is studying X-82 in a phase 1 trial to evaluate side effects and how well sequential dosing of X-82 and docetaxel works in treating patients with solid tumors.
X-82 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
For more information and to participate in this study, “Pharmacodynamic Study Using FLT-PET/CT in Patients With Advanced Solid Malignancies Treated With a Sequential Combination of X-82 and Docetaxel,” please visit clinicaltrials.gov NCT02146222.
Pancreatic Neuroendocrine Tumor & Renal Cell Carcinoma Trial
In partnership with Washington University School of Medicine, Tyrogenex is conducting a phase 1/2 trial to evaluate the combination of X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors and renal cell carcinoma.
For more information on this study, “A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors,” please visit clinicaltrials.gov NCT01784861.